BNT329 / BioNTech - LARVOL DELTA

BNT329-01: A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrialsregister.eu) - P1/2 | N=90 | Not yet recruiting | Sponsor: BioNTech SE

First-in-human • New P1/2 trial • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrials.gov) - P1/2 | N=245 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor • CA 19-9

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (clinicaltrials.gov) - P1/2 | N=245 | Not yet recruiting | Sponsor: BioNTech SE

First-in-human • New P1/2 trial • Oncology • Solid Tumor • CA 19-9